Trials / Terminated
TerminatedNCT00507637
Blepharospasm Short Interval
Prospective, Open-label, Single-arm, Single-center Trial to Investigate the Tolerability of NT 201 and Quality of Life of Patients in the Treatment of Blepharospasm With Shortened Injection Intervals
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Merz Pharmaceuticals GmbH · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this Phase II study is to show that pre-treated patients with BEB with the need of shortened injection intervals achieve an improved and stable quality of life level if they receive repeated NT 201 injections at short injection intervals. In addition, the tolerability of repeated shortened NT 201 administrations in patients with BEB including the development of neutralizing antibodies will be investigated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NT 201 | Injection of up to 50 Units NT 201 (incobotulinumtoxinA/Xeomin®) per eye and injection visit (8 injections visits in total). |
Timeline
- Start date
- 2007-08-01
- Primary completion
- 2008-02-01
- Completion
- 2008-02-01
- First posted
- 2007-07-26
- Last updated
- 2012-02-06
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00507637. Inclusion in this directory is not an endorsement.